Humulina Nph

Humulina Nph is a recombinant human insulin (rDNA) formulated as an injectable solution for subcutaneous or intramuscular administration. It is an intermediate‑acting (NPH) insulin marketed in the European Union. The product contains insulin human without added preservatives and is prescribed for managing blood glucose levels in diabetes. Humulina Nph is supplied as a sterile solution intended for use under medical supervision by qualified healthcare professionals.

Humulina Nph is indicated for the long‑term control of hyperglycemia in patients with diabetes.

- Type 1 diabetes mellitus as part of a basal insulin regimen. - Type 2 diabetes mellitus when basal insulin is required. - Adjunct to rapid‑acting insulin analogues for intensive insulin therapy. - Use in patients who need a predictable intermediate‑acting insulin profile. - May be combined with oral antidiabetic agents under physician guidance.

Adverse reactions to Humulina Nph vary in frequency and severity.

Common: - Mild hypoglycemia, especially if meals are delayed or skipped. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy (localized fat accumulation or loss) at the injection site. - Transient weight gain. - Nausea or mild gastrointestinal discomfort.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Persistent or severe injection site infections. - Hypersensitivity leading to bronchospasm or airway obstruction. - Edema or heart failure exacerbation in susceptible patients.

Humulina Nph should be used with careful monitoring and individualized dosing.

- Adjust dose based on blood glucose monitoring, dietary intake, and physical activity. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Assess for hypoglycemia risk in elderly, pregnant, or fasting individuals. - Avoid abrupt discontinuation; tapering may be required to prevent rebound hyperglycemia. - Monitor for signs of allergic reactions, especially after the first injection. - Educate patients on proper injection technique to minimize lipodystrophy. - Review concomitant use of other glucose‑lowering agents to avoid additive hypoglycemic effects.

Humulina Nph may interact with several medications that affect glucose metabolism.

Avoid: - Other insulin products or insulin secretagogues (e.g., sulfonylureas) without dose adjustment, due to increased hypoglycemia risk. - Beta‑blockers that mask hypoglycemia symptoms. - High‑dose corticosteroids that raise blood glucose levels.

Use with caution: - Oral antidiabetic agents (e.g., metformin, DPP‑4 inhibitors) – monitor glucose closely. - Diuretics that may alter electrolyte balance and affect insulin action. - ACE inhibitors or ARBs – may potentiate insulin’s glucose‑lowering effect. - Alcohol consumption – can cause unpredictable glucose fluctuations. - Thyroid hormones – hyperthyroidism may increase insulin requirements.